VEGF and EGFR TKIs in EGFR mutated NSCLC patients

Author Phase Line of Treatment Patients Treatment Response rate (%) Progression-free survival (months) Overall survival (months)
Seto et al. JO25567 trial [34, 35] II First 154 Erlotinib + bevacizumab vs. erlotinib 69 vs. 64, P = 0.49 16 vs. 9.7, HR: 0.54; 95% CI: 0.36-0.79 P = 0.0015 47 vs. 47.4, HR: 0.81; 95% CI: 0.53-1.23 P = 0.3267
Saito et al. NEJ026 trial [36] III First 228 Erlotinib + bevacizumab vs. erlotinib 72 vs. 66, P = 0.31 16.9 vs.13.3, HR: 0.605; 95% CI: 0.417-0877; P = 0.016. n.r.
Rosell et al. BELIEF [37] II First 109 Erlotinib + bevacizumab 77 13.2 (95% CI: 10.3-15.5) 28.2 (95% CI: 21.4-41.8)
Stinchcombe et al. [38] II First 88 Erlotinib + bevacizumab vs. erlotinib 81 vs. 83, P = 0.81 17.9 vs.13.5, HR: 0.81; 95% CI: 0.50-1.31; P =0.39 32.4 vs. 50.6, HR: 1.41; 95% CI: 0.71-2.81; P = 0.33
Ichihara et al. Okoyama trial [39] II First 42 Gefitinib + bevacizumab 73.8 (95% CI: 58.0-86.1) 14.4 (95% CI:10.1-19.2) n.r.
Kitigawa et al. [40] II First 16 Gefitinib-bevacizumab vs. gefitinib 44 vs. 50 5.4 (80% CI: 5.0-13.9) vs. 15.1 (80% CI: 6.2-23.5) 1-year OS: 0.667 (95% CI: 0.195-0.904) vs. 0.75 (95% CI: 0.315-0.931)
Hata et al. ABC trial [41] II Any line 32 Afatinib + bevacizumab 18.8 (95% CI: 7.2-36.4) 6.3 (95% CI: 3.9-8.7) n.r.
Nakagawa et al. RELAY trial [42] III First line 449 Erlotinib + Ramucirumab vs. Erlotinib 76 vs. 75, P = 0.741 19.4 vs. 12.4 HR: 0.59; 95% CI: 0.46-0.76, P < 0.0001 n.r.